Healthcare provider profile · identity verified

David W Sweiger, MD

Family Practice · MAPLE VALLEY, WA · NPI 1811903685

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	576	173
Lisinopril	Lisinopril	378	109
Metformin Hcl	Metformin Hcl	174	53
Amlodipine Besylate	Amlodipine Besylate	159	52
Losartan Potassium	Losartan Potassium	158	47
Levothyroxine Sodium	Levothyroxine Sodium	148	44
Tamsulosin Hcl	Tamsulosin Hcl	146	40
Metoprolol Succinate	Metoprolol Succinate	132	36
Ozempic	Semaglutide	97	13
Gabapentin	Gabapentin	94	31
Allopurinol	Allopurinol	92	25
Pantoprazole Sodium	Pantoprazole Sodium	89	25
Metformin Hcl Er	Metformin Hcl	76	23
Albuterol Sulfate Hfa	Albuterol Sulfate	74	27
Hydrochlorothiazide	Hydrochlorothiazide	73	28
Jardiance	Empagliflozin	72	19
Eliquis	Apixaban	71	16
Alendronate Sodium	Alendronate Sodium	66	19
Trazodone Hcl	Trazodone Hcl	66	17
Furosemide	Furosemide	55	15
Pravastatin Sodium	Pravastatin Sodium	55	17
Chlorthalidone	Chlorthalidone	54	16
Triamcinolone Acetonide	Triamcinolone Acetonide	50	22
Rosuvastatin Calcium	Rosuvastatin Calcium	42	12
Simvastatin	Simvastatin	41	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	41	12
Citalopram Hbr	Citalopram Hydrobromide	38	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	37	16
Finasteride	Finasteride	33	suppressed
Omeprazole	Omeprazole	33	suppressed
Sertraline Hcl	Sertraline Hcl	33	suppressed
Propranolol Hcl Er	Propranolol Hcl	32	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	30	11
Fluticasone Propionate	Fluticasone Propionate	29	12
Glipizide	Glipizide	28	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Xarelto	Rivaroxaban	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	26	suppressed
Glimepiride	Glimepiride	25	suppressed
Potassium Chloride	Potassium Chloride	25	suppressed
Carvedilol	Carvedilol	24	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	23	suppressed
Telmisartan	Telmisartan	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Ketoconazole	Ketoconazole	21	13
Arnuity Ellipta	Fluticasone Furoate	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Naproxen	Naproxen	20	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Atenolol	Atenolol	17	suppressed
Colchicine	Colchicine	17	11
Famotidine	Famotidine	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Prednisone	Prednisone	16	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error